KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Leases (2019 - 2025)

Historic Current Leases for Inovio Pharmaceuticals (INO) over the last 7 years, with Q3 2025 value amounting to $2.7 million.

  • Inovio Pharmaceuticals' Current Leases rose 1292.22% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 1292.22%. This contributed to the annual value of $2.5 million for FY2024, which is 377.47% up from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Current Leases stood at $2.7 million, which was up 1292.22% from $2.7 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' 5-year Current Leases high stood at $2.8 million for Q3 2022, and its period low was $2.1 million during Q3 2023.
  • For the 5-year period, Inovio Pharmaceuticals' Current Leases averaged around $2.5 million, with its median value being $2.5 million (2021).
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Current Leases plummeted by 2492.02% in 2023, and later skyrocketed by 1948.05% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Current Leases (Quarter) stood at $2.6 million in 2021, then grew by 7.68% to $2.8 million in 2022, then dropped by 14.17% to $2.4 million in 2023, then rose by 3.77% to $2.5 million in 2024, then rose by 9.66% to $2.7 million in 2025.
  • Its Current Leases stands at $2.7 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.6 million for Q1 2025.